NASDAQ:VCNX

Vaccinex - VCNX Stock Forecast, Price & News

Notice: Trading of Vaccinex halted at 11:01 AM EST due to "LULD pause".

$1.06

+0.03 (+2.91%)

(As of 08/8/2022 02:09 PM ET)

Add

Compare

Today's Range: $1.01
▼
$1.49
50-Day Range: $1.01
▼
$1.35
52-Week Range: $0.90
▼
$2.60

Volume: 45,438 shs
Average Volume: 596,004 shs
Market Capitalization: $45.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Vaccinex MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

1101st out of 1,293 stocks

Pharmaceutical Preparations Industry

525th out of 619 stocks

0.0

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vaccinex.

5.0

Short Interest

Percentage of Shares Shorted
1.31% of the float of Vaccinex has been sold short.
Short Interest Ratio / Days to Cover
Vaccinex has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vaccinex has recently decreased by 43.50%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vaccinex does not currently pay a dividend.
Dividend Growth
Vaccinex does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VCNX.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Vaccinex this week, compared to 1 article on an average week.
Search Interest
4 people have searched for VCNX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
1 people have added Vaccinex to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaccinex insiders have not sold or bought any company stock.
Percentage Held by Insiders
47.60% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
48.55% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Vaccinex is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaccinex is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaccinex has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vaccinex (NASDAQ:VCNX) Stock

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Vaccinex Price Performance

Shares of Vaccinex stock remained flat at $1.03 during trading on Monday. The company had a trading volume of 45,135 shares, compared to its average volume of 596,004. Vaccinex has a twelve month low of $0.90 and a twelve month high of $2.60. The company has a quick ratio of 10.00, a current ratio of 10.00 and a debt-to-equity ratio of 0.01. The stock has a market cap of $43.94 million, a price-to-earnings ratio of -2.00 and a beta of 0.99. The business's fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.25.

Vaccinex (NASDAQ:VCNX - Get Rating) last released its earnings results on Monday, May 16th. The company reported ($0.12) earnings per share (EPS) for the quarter.

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Stock News Headlines

August 4, 2022 | americanbankingnews.com

Vaccinex (NASDAQ:VCNX) and Ascendis Pharma A/S (NASDAQ:ASND) Head-To-Head Analysis

July 30, 2022 | seekingalpha.com

Stocks To Watch: Eyes On Starbucks, Caterpillar, And Amgen - Seeking Alpha

July 29, 2022 | globenewswire.com

Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease - GlobeNewswire

July 29, 2022 | finance.yahoo.com

Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease

July 29, 2022 | benzinga.com

Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease

July 21, 2022 | finance.yahoo.com

Multiple insiders bought Vaccinex, Inc. (NASDAQ:VCNX) stock earlier this year, a positive sign for shareholders

May 31, 2022 | benzinga.com

Vaccinex Shares Spike Higher; Co. Tweeted 'Vaccinex is currently conducting 2 ongoing clinical trials: ou - Benzinga

May 25, 2022 | finance.yahoo.com

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET - Yahoo Finance

May 25, 2022 | finance.yahoo.com

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

May 18, 2022 | globenewswire.com

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update - GlobeNewswire

May 17, 2022 | finance.yahoo.com

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update - Yahoo Finance

May 16, 2022 | finance.yahoo.com

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

April 25, 2022 | finance.yahoo.com

Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery

April 25, 2022 | globenewswire.com

Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery - GlobeNewswire

April 8, 2022 | seekingalpha.com

Catalyst watch: AACR meeting, Bed Bath & Beyond earnings and Elon Musk TED talk - Seeking Alpha

March 31, 2022 | globenewswire.com

Vaccinex Reports 2021 Financial Results and Provides Corporate Update - GlobeNewswire

March 31, 2022 | finance.yahoo.com

Vaccinex Reports 2021 Financial Results and Provides Corporate Update

March 15, 2022 | benzinga.com

Watching Vaccinex Shares Following US Patent & Trademark Office Abstract For Co.'s 'Anti-CD100 antibodies - Benzinga

March 9, 2022 | globenewswire.com

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 - GlobeNewswire

March 9, 2022 | finance.yahoo.com

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

February 27, 2022 | ca.finance.yahoo.com

Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting

February 24, 2022 | globenewswire.com

Vaccinex, Inc. to Present at CHDI's 17th Annual HD Therapeutics Conference Meeting - GlobeNewswire

February 24, 2022 | finance.yahoo.com

Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting - Yahoo Finance

February 24, 2022 | finance.yahoo.com

Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting

February 11, 2022 | finance.yahoo.com

With stock up 25%, Insiders of Vaccinex, Inc. (NASDAQ:VCNX) must be wishing they had bought more last year

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Company Calendar

Last Earnings: 5/16/2022
Today: 8/08/2022
Next Earnings (Estimated): 8/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VCNX
CUSIP: N/A
CIK: 1205922
Web: www.vaccinex.com
Phone: (585) 271-2700
Fax: 585-271-2765
Employees: 39
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,380,000.00
Net Margins: N/A
Pretax Margin: -40,802.00%
Return on Equity: -155.64%
Return on Assets: -121.90%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 10.00
Quick Ratio: 10.00

Sales & Book Value

Annual Sales: $900,000.00
Price / Sales: 50.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.24 per share
Price / Book: 4.42

Miscellaneous

Outstanding Shares: 42,664,000
Free Float: 22,356,000
Market Cap: $45.22 million
Optionable: Not Optionable
Beta: 0.99

Key Executives

Dr. Maurice Zauderer Ph.D. (Age 76)
Co-Founder, CEO, Pres & Director
Comp: $374.9k
Mr. Scott E. Royer C.F.A. (Age 48)
M.B.A., Chief Financial Officer
Comp: $242.15k
Dr. Ernest S. Smith Ph.D. (Age 50)
Sr. VP of Research & Chief Scientific Officer
Comp: $264.74k
Dr. Deepak M. Sahasrabudhe
Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
Dr. Elizabeth E. Evans Ph.D. (Age 49)
COO and Sr. VP of Discovery & Translational Medicine
Dr. John E. Leonard Ph.D. (Age 75)
Sr. VP of Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VCNX Stock - Frequently Asked Questions

How has Vaccinex's stock performed in 2022?: Vaccinex's stock was trading at $1.04 on January 1st, 2022. Since then, VCNX stock has increased by 14.4% and is now trading at $1.19.
View the best growth stocks for 2022 here.
Are investors shorting Vaccinex?: Vaccinex saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 280,500 shares, a decline of 43.5% from the June 30th total of 496,500 shares. Based on an average daily volume of 95,700 shares, the short-interest ratio is presently 2.9 days. Approximately 1.3% of the company's stock are sold short.
View Vaccinex's Short Interest.
When is Vaccinex's next earnings date?: Vaccinex is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our VCNX earnings forecast.
How were Vaccinex's earnings last quarter?: Vaccinex, Inc. (NASDAQ:VCNX) released its quarterly earnings results on Monday, May, 16th. The company reported ($0.12) earnings per share (EPS) for the quarter.
What other stocks do shareholders of Vaccinex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?: (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.
What is Vaccinex's stock symbol?: Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."
How do I buy shares of Vaccinex?: Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vaccinex's stock price today?: One share of VCNX stock can currently be purchased for approximately $1.19.
How much money does Vaccinex make?: Vaccinex (NASDAQ:VCNX) has a market capitalization of $50.77 million and generates $900,000.00 in revenue each year. The company earns $-22,380,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.
How many employees does Vaccinex have?: Vaccinex employs 39 workers across the globe.
How can I contact Vaccinex?: Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The official website for the company is www.vaccinex.com. The company can be reached via phone at (585) 271-2700, via email at mrice@lifesciadvisors.com, or via fax at 585-271-2765.

This page (NASDAQ:VCNX) was last updated on 8/8/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Vaccinex - VCNX Stock Forecast, Price & News

Vaccinex MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vaccinex (NASDAQ:VCNX) Stock

Vaccinex Price Performance

VCNX Stock News Headlines

VCNX Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VCNX Stock - Frequently Asked Questions

How has Vaccinex's stock performed in 2022?

Are investors shorting Vaccinex?

When is Vaccinex's next earnings date?

How were Vaccinex's earnings last quarter?

What other stocks do shareholders of Vaccinex own?

When did Vaccinex IPO?

What is Vaccinex's stock symbol?

How do I buy shares of Vaccinex?

What is Vaccinex's stock price today?

How much money does Vaccinex make?

How many employees does Vaccinex have?

How can I contact Vaccinex?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™